Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
The live call may be accessed by dialing 877-407-3103 (
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.
Senior Vice President
Source: Bellicum Pharmaceuticals, Inc.